Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo

Background: More than 90 tyrosine kinases have been implicated in the pathogenesis of malignant transformation and tumor angiogenesis. Tyrosine kinase inhibitors (TKIs) have emerged as effective therapies in treating cancer by exploiting this kinase dependency. The TKI erlotinib targets the epiderma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Brian C., Parry, Traci L., Huang, Wei, Ilaiwy, Amro, Bain, James R., Muehlbauer, Michael J., O’Neal, Sara K., Patterson, Cam, Johnson, Gary L., Willis, Monte S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618316/
https://www.ncbi.nlm.nih.gov/pubmed/28640223
http://dx.doi.org/10.3390/metabo7030031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618316/
https://www.ncbi.nlm.nih.gov/pubmed/28640223
http://dx.doi.org/10.3390/metabo7030031

Ejemplares similares